Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR

Indian Journal of Medical Research

Volumn 137, Issue 2, 2013, Pages 243-246

  Maiese, Kenneth ^a,b,c  

^a Laboratory of Cellular and Molecular Signaling   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c New Jersey Health Sciences University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; TEMSIROLIMUS;

APOPTOSIS; AUTOPHAGY; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NERVE DEGENERATION; OXIDATIVE STRESS;

APOPTOSIS; AUTOPHAGY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; TOR SERINE-THREONINE KINASES;

EID: 84875523447     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (24)

1. Chong ZZ, Shang YC, Wang S, Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 2012; 99: 128-48.
2. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005; 280: 25485-90.
3. Chong ZZ, Shang YC, Wang S, Maiese K. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS ONE 2012; 7: e45456.
4. Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Therapeutic Targets 2012; 16: 1203-14.
5. Chung CY, Park YL, Song YA, Myung E, Kim KY, Lee GH, et al. Knockdown of RON inhibits ap-1 activity and inducesapoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. Dig Dis Sci 2012; 57: 371-80.
6. Hou J, Chong ZZ, Shang YC, Maiese K. FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol 2010; 321: 194-206.
7. Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 2009; 5: 973-9.
8. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009; 20: 1992-2003.
9. Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med 2013; 19: 51-60.
10. Kapoor V, Zaharieva MM, Das SN, Berger MR. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett 2012; 319: 39-48.
11. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010; 116: 4980-90.
12. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-80.
13. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res 2012; 10: 649-59.
14. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008; 18: 56-62.
15. Curran MP. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs 2012; 14: 51-60.
16. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-11.
17. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-12.
18. Sanchez-Fructuoso AI, Ruiz JC, Calvo N, Rodrigo E, Perez-Flores I, Gomez-Alamillo C, et al. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors. Transplantation 2012; 93: 398-405.
19. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009; 94: 4107-12.
20. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777-82.
21. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/Mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiat Oncol 2012; 7: 48-60.
22. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246-56.
23. Shang YC, Chong ZZ, Wang S, Maiese K. WNT1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern beta-amyloid apoptotic injury of microglia. Curr Neurovasc Res 2012; 9: 239-49.
24. Shang Y, Chong Z, Wang S, Maiese K. Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia. Curr Neurovasc Res 2013; 10: 29-38.